Expert Review of Vaccines

Papers
(The H4-Index of Expert Review of Vaccines is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada93
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy85
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?69
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States61
Indirect protection from rotavirus vaccines: a systematic review55
Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study54
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response53
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic48
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children45
Vaccines against chronic Trypanosoma cruzi infection: progress, challenges and future directions45
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays44
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom43
Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China40
Epidemiological shifts in coxsackievirus A-induced hand, foot, and mouth disease in China, 2008–202440
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review37
Addressing barriers to and strategies for herpes zoster vaccination in immunocompromised patients in Türkiye: an expert consensus37
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection33
Microarray patches: scratching the surface of vaccine delivery31
Recent advances for the pharmaceutical production of highly attenuated poxviruses as viral vector platforms30
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis30
The important lessons lurking in the history of meningococcal epidemiology29
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era28
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China27
Off-Label use of vaccines may save lives and money: lessons from the province of Quebec, Canada26
Montanide ISA-51: a promising adjuvant in cancer vaccine immunotherapy26
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond26
Addressing RSV infection in older adults: implications for public health policy26
Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany26
0.13421893119812